Phase 3 Migraine Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have completed the Week 12 final visit of one of two specific earlier related studies (Study 19356A or Study 19357A) immediately before enrolling in this trial.
Who may not be able to join:
- People who experienced side effects or safety concerns during the earlier study that the trial doctor believes were caused by the study treatment and pose an ongoing safety risk.
- People who had a severe allergic reaction (such as anaphylaxis) or another serious allergic response to the study drug infusion during the earlier study, as determined by the trial doctor.
- People who had liver enzyme levels (ALT or AST) rise above 5 times the normal upper limit during the earlier study, confirmed by a second test taken within 2 weeks.
- People who had liver enzyme levels (ALT or AST) rise above 3 times the normal upper limit AND a specific measure of liver function (total bilirubin) rise above 2 times the normal upper limit during the earlier study.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Email contact via H. Lundbeck A/S, H. Lundbeck A/S
Phone: +45 36301311
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Number of Participants With Treatment Emergent Adverse Events
Can't join this trial?
Data last synced from ClinicalTrials.gov: 16 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.